{
    "symbol": "COLL",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-06 06:39:04",
    "content": " These actions include executing training to strengthen the knowledge and impact of our sales professionals, launching new educational resources for our sales team to use during their interactions with HCPs and pharmacists; introducing new non-personal promotional content and channels, which reinforce the clinical differentiation of Xtampza ER and BELBUCA; launching new personal and non-personal promotional tools to pull through the strong access positions of Xtampza ER and BELBUCA and supporting payers as they ensure that the value of Xtampza ER is clearly understood enabling stronger formulary controls where Xtampza ER is exclusive."
}